RIGEL PHARMACEUTICALS INC

RIGL · Nasdaq · SIC 2834: Pharmaceutical Preparations
324
SEC Filings

Business Summary

Rigel Pharmaceuticals is a biotechnology company focused on developing and commercializing novel therapies for hematologic disorders and cancer. Its FDA-approved products include TAVALISSE (fostamatinib), an oral SYK inhibitor for chronic ITP; REZLIDHIA (olutasidenib), for relapsed/refractory AML with IDH1 mutation; and GAVRETO (pralsetinib), for metastatic RET fusion-positive NSCLC and advanced thyroid cancer. Its pipeline includes R289, a dual IRAK1/4 inhibitor in Phase 1b for lower-risk MDS.

Next Earnings

Q2 FY2026 — expected 2026-08-07

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionRIGLdiscussed_in_filing Cybersecurity
topic_mentionRIGLdiscussed_in_filing Trusted Computing
topic_mentionRIGLdiscussed_in_filing Blockchain & Crypto
topic_mentionRIGLdiscussed_in_filing Regulation
topic_mentionRIGLdiscussed_in_filing Healthcare & Bio
topic_mentionRIGLdiscussed_in_filing Sovereign & Government
topic_mentionRIGLdiscussed_in_filing Cybersecurity
topic_mentionRIGLdiscussed_in_filing Trusted Computing
topic_mentionRIGLdiscussed_in_filing Blockchain & Crypto
topic_mentionRIGLdiscussed_in_filing Regulation
topic_mentionRIGLdiscussed_in_filing Healthcare & Bio
topic_mentionRIGLdiscussed_in_filing Sovereign & Government
topic_mentionRIGLdiscussed_in_filing Cybersecurity
topic_mentionRIGLdiscussed_in_filing Trusted Computing
topic_mentionRIGLdiscussed_in_filing Blockchain & Crypto
topic_mentionRIGLdiscussed_in_filing Regulation
topic_mentionRIGLdiscussed_in_filing Healthcare & Bio
topic_mentionRIGLdiscussed_in_filing Sovereign & Government
topic_mentionRIGLdiscussed_in_filing Cybersecurity
topic_mentionRIGLdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-032025-12-310001034842-26-000015EDGAR99K words
2025-03-042024-12-310001558370-25-002169EDGAR—
2024-03-052023-12-310001558370-24-002475EDGAR—
2023-03-072022-12-310001558370-23-003035EDGAR—
2022-03-012021-12-310001558370-22-002551EDGAR—
2021-03-022020-12-310001558370-21-002254EDGAR—
2020-02-272019-12-310001558370-20-001624EDGAR—
2019-02-282018-12-310001558370-19-001310EDGAR—
2018-03-062017-12-310001558370-18-001555EDGAR—
2017-03-072016-12-310001558370-17-001428EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300001104659-25-106268EDGAR73K words
2025-08-052025-06-300001558370-25-010281EDGAR—
2025-05-062025-03-310001558370-25-006493EDGAR—
2024-11-072024-09-300001558370-24-014862EDGAR—
2024-08-062024-06-300001558370-24-011079EDGAR—
2024-05-072024-03-310001558370-24-007041EDGAR—
2023-11-072023-09-300001558370-23-017987EDGAR—
2023-08-012023-06-300001558370-23-012722EDGAR—
2023-05-022023-03-310001558370-23-007653EDGAR—
2022-11-032022-09-300001558370-22-016266EDGAR—
2022-08-022022-06-300001558370-22-011638EDGAR—
2022-05-032022-03-310001558370-22-006809EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-030001034842-26-000016EDGAR4K words
2026-02-030001034842-26-000007EDGAR—
2026-01-120001034842-26-000005EDGAR—
2025-12-100001104659-25-119976EDGAR—
2025-11-040001104659-25-106282EDGAR—
2025-08-050001104659-25-074163EDGAR—
2025-05-230001104659-25-052407EDGAR—
2025-05-060001104659-25-045067EDGAR—
2025-03-270001104659-25-028564EDGAR—
2025-03-100001104659-25-022224EDGAR—

324 total filings indexed. 292 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

hematology oncology immune-thrombocytopenia-(itp) acute-myeloid-leukemia-(aml) non-small-cell-lung-cancer-(nsclc) thyroid-cancer myelodysplastic-syndrome-(mds)

Company Identity

CIK0001034842
TickerRIGL
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a328b422889f6f8830d872141322f33d622165eea78964d4853abd70af31325e
parent: 5e497f5177bd5eea5836ec190a9634fd1e749cc68cea8ba2aac3081f0fab3dce
content hash: a1b0bfbd77d0ca5719f14120d51157cf0aac123a79323a9b607380a73686017a
signed: 2026-04-13T04:47:11.771Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf